Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting Non-phase study NCT07619170

EasiVits Acceptability & Tolerance Study

EasiVits Acceptability & Tolerance Study — Active Not Recruiting • Non-phase study • Diabetes / Metabolic • NCT07619170.

📅 01 Jun 2026 ⏱ 2 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Non-phase study
NCT ID
NCT07619170
Start
2026-03-07
Completion
2026-09-23
ClinicaliQ Trial Snapshot
  • EasiVits Acceptability & Tolerance Study — Active Not Recruiting • Non-phase study • Diabetes / Metabolic • NCT07619170.
  • EasiVits trial tested new low-carbohydrate, unflavoured vitamin supplements designed to improve adherence in children with metabolic disorders requiring restricted diets.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

In order to achieve metabolic stability, dietary treatment of inborn errors of metabolism (IEM) may require restriction of protein (e.g. phenylketonuria, tyrosinaemia, homocystinuria, organic acidaemias, maple syrup urine disease (MSUD), urea cycle disorders), fat (e.g. fatty acid oxidation disorders) or carbohydrate (e.g. glycogen storage disease). Manipulation of dietary intake potentially reduces micronutrient status, and provision of a comprehensive vitamin and mineral supplement may become an essential adjunct to dietary treatment. Paediatric Seravit and Frutivits are vitamin and mineral supplements that are currently available on prescription. Paediatric Seravit is designed for…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Insulin pumps and continuous glucose monitoring (CGM) equipment: guidance for users on reporting suspected adverse incidents and safety concerns to the MHRA’s Yellow Card scheme
Diabetes / Metabolic · MHRA · 24 Oct 2024
We ask healthcare professionals to support new guidance for users of diabetes management equipment, their families, care givers and representatives. This update…
View brief →
Clinical Brief
New light shed on who benefits most from weight-loss jabs
Diabetes / Metabolic · BBC Health · 08 Apr 2026
People who carry variations in two genes linked to appetite and digestion can lose more weight when taking drugs to treat obesity,…
View brief →
Guideline
Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management
Diabetes / Metabolic · 06 Jul 2016
Assess all patients with MASLD using FIB-4 index or transient elastography to stratify fibrosis risk—those with advanced fibrosis require specialist hepatology referral…
View guideline →
Clinical Brief
New drug to stop ‘Ozempic butt’ muscle loss side effect of obesity jabs
Diabetes / Metabolic · BBC Health · 08 Jun 2026
Weight loss from GLP-1 receptor agonists results in approximately 33% muscle loss alongside fat loss, necessitating clinical attention to body composition changes…
View brief →
Clinical Brief
Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error
Diabetes / Metabolic · MHRA · 17 Dec 2025
Rybelsus ® (semaglutide tablets): transition to new formulation and risk of med...
View brief →
Guideline
Non-Alcoholic Fatty Liver Disease: Assessment and Management (NICE NG49)
Diabetes / Metabolic · 27 Mar 2026
Use FIB-4 or NAFLD Fibrosis Score in primary care to stratify fibrosis risk in adults with metabolic risk factors (type 2 diabetes,…
View guideline →